Loading
A phase 3 trial of Atirmociclib, Abemaciclib, Palbociclib and Ribociclib in HR-positive / HER2-negative breast cancer, run by Pfizer, active and no longer recruiting.
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease is a phase 3 interventional study registered as NCT06760637 by Pfizer, with 1035 participants enrolled, started 2025-01-06 and due to reach its primary completion in 2029-01-02. Interventions recorded: PF-07220060, letrozole, abemaciclib, palbociclib and ribociclib.
Shares Atirmociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen) and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Atirmociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen) and the tag pipeline.
Shares Ribociclib, Palbociclib, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Palbociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen) and the tag pipeline.
Shares Ribociclib, Abemaciclib, Palbociclib and the tag pipeline.
Shares Ribociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen) and the tag pipeline.